Larry Loo1, Georgio Vrakas, Srikanth Reddy, Philip Allan. 1. aTranslational Gastroenterology Unit, John Radcliffe Hospital bOxford Transplant Centre, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Abstract
PURPOSE OF REVIEW: The purpose of this article is to review the existing literature on the current indications, surgical techniques, immunosuppressive therapy and outcomes following intestinal transplantation (ITx). RECENT FINDINGS: Over recent years, ITx has become a more common operation with approximately 2500 procedures carried out worldwide by 2014. It is reserved for patients with intestinal failure and who have developed complications of home parenteral nutrition or who have a high risk of dying from their underlying disease. Recent advances such as the improvement in survival rates, not only for isolated small bowel transplants but also following inclusion of a liver graft in combined liver-small bowel transplant, and the utility of citrulline as a noninvasive biomarker to appreciate acute rejection herald an exciting shift in the field of ITx. SUMMARY: With advancements in immunosuppressive drugs, induction regimens, standardization of surgical techniques and improved postoperative care, survival is increasing. In due course, it will most likely become as good as remaining on home parenteral nutrition and as such could become a viable first-line option.
PURPOSE OF REVIEW: The purpose of this article is to review the existing literature on the current indications, surgical techniques, immunosuppressive therapy and outcomes following intestinal transplantation (ITx). RECENT FINDINGS: Over recent years, ITx has become a more common operation with approximately 2500 procedures carried out worldwide by 2014. It is reserved for patients with intestinal failure and who have developed complications of home parenteral nutrition or who have a high risk of dying from their underlying disease. Recent advances such as the improvement in survival rates, not only for isolated small bowel transplants but also following inclusion of a liver graft in combined liver-small bowel transplant, and the utility of citrulline as a noninvasive biomarker to appreciate acute rejection herald an exciting shift in the field of ITx. SUMMARY: With advancements in immunosuppressive drugs, induction regimens, standardization of surgical techniques and improved postoperative care, survival is increasing. In due course, it will most likely become as good as remaining on home parenteral nutrition and as such could become a viable first-line option.
Authors: Pablo Stringa; David Romanin; Natalia Lausada; Rodrigo Papa Gobbi; Carolina Zanuzzi; Pedro Martín; Juan Cruz Abate; Ana Cabanne; Nathalie Arnal; Leandro Vecchio; Verónica Milesi; Enrique Portiansky; Gabriel Gondolesi; Martin Rumbo Journal: Transplant Direct Date: 2017-10-06
Authors: Nadja Stobutzki; Stephan Schlickeiser; Mathias Streitz; Katarina Stanko; Kim-Long Truong; Levent Akyuez; Katrin Vogt; Christine Appelt; Andreas Pascher; Olga Blau; Undine A Gerlach; Birgit Sawitzki Journal: Front Immunol Date: 2019-05-07 Impact factor: 7.561
Authors: Carlos L Correa-Martínez; Felix Becker; Vera Schwierzeck; Alexander Mellmann; Jens G Brockmann; Stefanie Kampmeier Journal: Antimicrob Resist Infect Control Date: 2020-11-07 Impact factor: 4.887
Authors: Ibitamuno Caleb; Luca Erlitz; Vivien Telek; Mónika Vecsernyés; György Sétáló; Péter Hardi; Ildikó Takács; Gábor Jancsó; Tibor Nagy Journal: Metabolites Date: 2021-06-17
Authors: Elizabeth Abou Diwan; Ankit B Patel; Alex G Cuenca; Nahel Elias; Hannah M Gilligan; Eliot Heher; David E Leaf; David Wojciechowski; Kassem Safa Journal: Case Rep Transplant Date: 2020-10-05